Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24439324 | 0.83 | NOX1 (0.43) | SMN1; SMN2GAANOX1MAPTNPSR1 | |
| SCHEMBL30725915 | 0.83 | NOX1 (0.43) | SMN1; SMN2GAANOX1MAPTNPSR1 | |
| SCHEMBL11375504 | 0.81 | BCHE (0.44) | MAPTBCHEACHE | |
| SCHEMBL24439587 | 0.81 | SNCA (0.43) | HSD17B3SMN1; SMN2GAANOX1MAPT | |
| SCHEMBL24439580 | 0.80 | P2RX4 (0.43) | HSD17B3SMN1; SMN2GAANOX1MAPT | |
| SCHEMBL30725909 | 0.80 | P2RX4 (0.43) | HSD17B3SMN1; SMN2GAANOX1MAPT | |
| SCHEMBL23051919 | 0.77 | OPRK1 (0.35) | SMN1; SMN2GAAMAPTNPSR1 | |
| SCHEMBL11371326 | 0.75 | BCHE (0.38) | MAPTBCHEACHE | |
| SCHEMBL11369729 | 0.75 | BCHE (0.38) | BCHEACHE | |
| SCHEMBL11384247 | 0.74 | NR1I3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025868-A1 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025868-A1 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025868-A1 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2022104070-A2 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025868-A1 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | ACE2, BACE2, PSEN2 | HSD17B3 2752/4885SMN1; SMN2 203/4885GAA 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.